

March 12, 2021

Exhibit 1: Latest Financials

(Rs mn)	9MFY21	9MFY20	YoY gr.
Specialty Chemicals	8180	8310	-2%
Nutrition and Health	4310	3730	16%
Life Science Chemicals	11650	11510	1%
Total revenue	24140	23550	3%
EBITDA	4180	3130	34%
EBITDA %	17%	13%	
Finance Cost	590	640	-8%
Profit After Tax	2210	1720	28%

Source: Company, PL

Jubilant Ingrevia

Analyst Meet Update

Improvement in global demand and pricing of molecules holds key for growth

Quick Pointers:

- Demerged Life Science Ingredients (LSI) business of Jubilant Life Sciences to Jubilant Ingrevia to unlock shareholder value.
- To list on stock exchange by Mar-21

JUBILANT INGREVIA hosted an analyst meet ahead of its listing on exchanges, expected in March-CY21. Management guided 1) double digit growth in revenue over FY21-23E, 2) improvement in EBITDAM from current 9MFY21 17% to 20%+ in coming years, 3) net debt reduction and 4) CAPEX of Rs5.5bn/Rs1bn/Rs2.5bn for Specialty/Nutrition/LSI segment in 3 years. Its future growth is dependent on revenue originating from three main sources: Specialty chemicals, Nutrition/Health solutions and Life science chemicals (LSI). While its key products Pyridine & derivatives, Niacin & Niacinamide and Vit-B complex are under pricing pressure with low volume demand (since FY19), management expects improvement led by China increasing prices of selected chemical products. We value JUBILANT INGREVIA at Rs402/ share based on 10x (earlier 3x) EV/EBITDA FY23E. We estimate EBITDA of Rs6.7bn in FY23E. We increase our EV/EBITDA multiple assigned to JUBILANT INGREVIA and bring in-line with listed specialty chemicals players as 1) it reduced net reduced debt ahead of its guidance in last 18 months 2) foray into specialty chemicals and 3) improved outlook in its key molecules.

Exhibit 2: LSI Segment Valuation

EBITDA(FY23)-(Rs mn)	6,796
EV/EBITDA Multiple	10
Net Debt(Rs mn)	5,290
Enterprise Value (Rs mn)	62,672
Share Outstanding(mn)	156
Per Share Value(Rs)	402
Source: Company DI	

Source: Company, PL

Meeting Highlights:

- It does not have client concentration risk as top 10 customers contribute only 20% of revenue.
- Currently operating at 80-85% utilization level in all three segments and is in advance stage for further expansion. New capacity would come on stream from 3QFY22E onwards.
- Investment decision is based on payback period of 3 years.
- Current gross debt/net debt stands at Rs7bn/Rs5.2bn.


Surajit Pal

surajitpal@plindia.com | 91-22-66322259

Tausif Shaikh

tausifshaikh@plindia.com | 91-22-66322246

Exhibit 3: Business Mix (9MFY21 Sales)



Source: Company, PL

Exhibit 4: Business details

	Highlights	Entry Barriers
Speciality Chemicals	 Portfolio of ~70 products Amongst top 2 in Pyridine - Beta globally #1 in 11 Pyridine Derivatives globally 'Partner of Choice' in CDMO services with a strong pipeline Catering ~420 customers globally 	 Globally lowest cost producer of Pyridine – Beta & all value added products Long approval process of customers, takes about 3-5 years for product approvals and facility audit Demonstrated expertise in handling multi-step chemistries (~13 steps) upto commercial scale
Nutrition & Health Solution	 Portfolio of 34 products Amongst top 2 in Vitamin B3 (Niacinamide) globally Serving diverse customers in Animal & Human Nutrition, Personal Care, etc #1 in Vitamin B4 (Choline Chloride) domestic market Offer more than 18 branded solutions to farmers & channel partners Catering ~400 customers globally 	 Complete backward integration to key RM i.e. Beta Picoline & Differentiated niche technology (air oxidation for mfg of Niacinamide – leading to lowest cost Attained deep reach to farmer community for Anima Nutrition & Health products Brand Recognition –"ANICHOL" for Vit-B4 is leading brand & other 18 Brands
Life Science Chemicals	 Portfolio of 6 products Amongst top 2 in Acetic Anhydride globally Leading producer of Ethyl Acetate Globally largest manufacturer of bio-based Acetaldehyde Most reliable player of Acetyl products from multi-plants at multi-locations Catering ~600 customers globally 	 Capability of handling large "Ketene" volumes Strong internal systems to manage controlled substances

Source: Company, PL


32

JUBILANT

Exhibit 5: Revenue breakup


Diverse & De-risked Business Model

- De-risked business model benefits from its diversified product offerings, product sourcing capabilities as well as a broad customer base with a world class manufacturing and global marketing footprint
- Presence across geographic locations enables us to serve different market segments



Source: Company, PL


Exhibit 6: Specialty Chemicals



Source: Company, PL

- Globally Ingrevia has a wide range of products in Pyridines, Picolines & its derivatives (~70 products). It ranks amongst top 2 in Pyridine-Beta and globally #1 in 11 Pyridine Derivatives.
- Utilising ~ 45% of Pyridine & Picolines' production for captive use to produce value added products.
- Long term relationship with customers in Pharma, Agro & Consumer applicationstakes about 3-5 years for product approvals/audits.


Exhibit 7: Nutrition & Health Solutions



Source: Company, PL

- Globally #1 producer of Niacinamide and amongst Global top 2 manufacturers of Vitamin B3. It is India's largest manufacturer of Vitamin B4 (Choline Chloride).
- It sources entire of Beta Picoline (the key RM in-house for production of Vitamin B3 (Niacimanide & Niacin)

Exhibit 8: Life Science Chemicals



Source: Company, PL

- Globally among top-2 manufacturers of Acetic Anhydride and Propionic Anhydride in merchant market.Leader in domestic market in Acetic Anhydride and Ethyl Acetate since last 4 decades.
- World's largest manufacturer of Bio-Acetaldehyde.

Jubilant Ingrevia

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aurobindo Pharma	Accumulate	1,061	935
2	Cadila Healthcare	Accumulate	522	475
3	Cipla	Accumulate	913	826
4	Dr. Lal PathLabs	UR	-	2,407
5	Dr. Reddy's Laboratories	BUY	5,406	4,603
6	Eris Lifesciences	BUY	666	621
7	Glenmark Pharmaceuticals	Sell	446	491
8	Indoco Remedies	BUY	358	314
9	Ipca Laboratories	Accumulate	2,257	1,932
10	Jubilant Pharmova	Accumulate	1,088	916
11	Lupin	BUY	1,287	1,049
12	Sun Pharmaceutical Industries	BUY	672	586
13	Thyrocare Technologies	UR	-	970

PL's Recommendation Nomenclature

-	> 15% 5% to 15%
:	+5% to -5%
:	-5% to -15%
:	< -15%
:	No specific call on the stock
:	Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to statisfy the regulatory licensing requirements of FINRA or required to otherwise account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com